Auris Medical Holding AG (NASDAQ:EARS)‘s stock had its “hold” rating reissued by equities researchers at JMP Securities in a note issued to investors on Friday.

EARS has been the subject of a number of other research reports. Needham & Company LLC raised their target price on shares of Auris Medical Holding AG from $5.00 to $11.00 and gave the stock a “buy” rating in a research note on Friday, August 19th. Zacks Investment Research cut shares of Auris Medical Holding AG from a “hold” rating to a “sell” rating in a research note on Monday, September 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $8.06.

Auris Medical Holding AG (NASDAQ:EARS) opened at 1.196 on Friday. The stock’s 50 day moving average is $1.32 and its 200-day moving average is $2.79. Auris Medical Holding AG has a 12 month low of $0.84 and a 12 month high of $7.96. The firm’s market capitalization is $41.04 million.

Auris Medical Holding AG (NASDAQ:EARS) last posted its earnings results on Thursday, November 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. During the same quarter last year, the firm posted ($0.15) EPS. Equities analysts anticipate that Auris Medical Holding AG will post ($1.05) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Auris Medical Holding AG stock. TFS Capital LLC increased its stake in shares of Auris Medical Holding AG (NASDAQ:EARS) by 17.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,230 shares of the company’s stock after buying an additional 5,762 shares during the period. TFS Capital LLC owned about 0.11% of Auris Medical Holding AG worth $160,000 as of its most recent filing with the SEC. 26.82% of the stock is owned by hedge funds and other institutional investors.

Auris Medical Holding AG Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

5 Day Chart for NASDAQ:EARS

Receive News & Stock Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related stocks with our FREE daily email newsletter.